Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $15.2500 (-7.13%) ($15.1800 - $16.5300) on Thu. Aug. 10, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.33% (three month average) | RSI | 25 | Latest Price | $15.2500(-7.13%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -2.1% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(24%) IBB(22%) XOP(18%) ARKG(17%) IWC(17%) | Factors Impacting ADMS price | ADMS will decline at least -1.165% in a week (0% probabilities). VIXM(-11%) UUP(-11%) UNG(-9%) BNDX(-7%) TLT(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.165% (StdDev 2.33%) | Hourly BBV | 0 () | Intraday Trend | -7.3% | | | |
|
1 - 5 Day Possible Target | $9.34(-38.75%) | Resistance Level | $17.23 | 5 Day Moving Average | $16.55(-7.85%) | 10 Day Moving Average | $16.88(-9.66%) | 20 Day Moving Average | $17.23(-11.49%) | To recent high | -17.3% | To recent low | 3.5% | Market Cap | $431m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |